复星医药(02196)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02196 复星医药

已收盘 03-26 16:08:17

18.790

-0.150

-0.79%

最高19.360	最低18.620	成交量273.50万
今开19.060	昨收18.940	日振幅3.91%
总市值499.63亿	流通市值101.65亿	总股本26.59亿
成交额5,181万	换手率0.51%	流通股本5.41亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02196","market":"HK","secType":"STK","nameCN":"复星医药","latestPrice":18.79,"timestamp":1774512497003,"preClose":18.94,"halted":0,"volume":2735000,"delay":0,"changeRate":-0.007919746568109932,"floatShares":540971500,"shares":2659000000,"eps":1.4368806097456002,"marketStatus":"已收盘","change":-0.15,"latestTime":"03-26 16:08:17","open":19.06,"high":19.36,"low":18.62,"amount":51809908,"amplitude":0.039071,"askPrice":18.79,"askSize":5000,"bidPrice":18.77,"bidSize":2000,"shortable":3,"etf":0,"ttmEps":1.4368806097456002,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1774575000000},"marketStatusCode":5,"adr":0,"listingDate":1351526400000,"exchange":"SEHK","adjPreClose":18.94,"dividendRate":0.019286,"openAndCloseTimeList":[[1774488600000,1774497600000],[1774501200000,1774512000000]],"volumeRatio":1.128058,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"600196","market":"SH","secType":"STK","nameCN":"复星医药","latestPrice":25.29,"timestamp":1774508400000,"preClose":25.36,"halted":0,"volume":14237900,"delay":0,"premium":"-34.33"}},"requestUrl":"/m/hq/s/02196","defaultTab":"news","newsList":[{"id":"2622000486","title":"复星医药（600196）2025年年报简析：营收净利润同比双双增长，盈利能力上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2622000486","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622000486?lang=zh_cn&edition=full","pubTime":"2026-03-26 06:02","pubTimestamp":1774476154,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期复星医药发布2025年年报。截至本报告期末，公司营业总收入416.62亿元，同比上升1.45%，归母净利润33.71亿元，同比上升21.69%。按单季度数据看，第四季度营业总收入122.68亿元，同比上升20.81%，第四季度归母净利润8.47亿元，同比上升11.59%。本报告期复星医药盈利能力上升，毛利率同比增幅4.38%，净利率同比增幅19.21%。该数据高于大多数分析师的预期，此前分析师普遍预期2025年净利润为盈利33.58亿元左右。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032600006043.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600196","02196"],"gpt_icon":0},{"id":"1152396741","title":"异动解读 | 复星医药盘中大涨5.21%，2025年净利润增长21.69%并派息提振股价","url":"https://stock-news.laohu8.com/highlight/detail?id=1152396741","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1152396741?lang=zh_cn&edition=full","pubTime":"2026-03-25 09:46","pubTimestamp":1774403208,"startTime":"0","endTime":"0","summary":"复星医药今日盘中大幅上涨5.21%，引起了市场的广泛关注。消息面上，公司于前一日晚间及今日早间陆续发布了2025年年度报告。报告显示，2025年公司实现归属于上市公司股东的净利润33.71亿元人民币，同比增长21.69%；基本每股收益1.27元，同比增长22.12%。此外，根据年报披露，公司创新药品收入在2025年达到98.93亿元，同比增长29.59%，成为业绩增长的重要引擎。全年研发总投入59.13亿元，其中创新药相关研发投入持续增长。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02196"],"gpt_icon":0},{"id":"2622401171","title":"复星医药(02196)拟派发末期股息每股0.39元","url":"https://stock-news.laohu8.com/highlight/detail?id=2622401171","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622401171?lang=zh_cn&edition=full","pubTime":"2026-03-25 07:34","pubTimestamp":1774395268,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药(02196)发布公告，该公司拟派发末期股息每股0.39元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1418426.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["600196","BK0175","BK0188","BK4585","VIG","BK0187","BK1515","BK0012","BK0028","02196","BK0060","BK0096","BK1191","BK1593","BK4588","BK0239","BK0183","BK0196"],"gpt_icon":0},{"id":"2621067566","title":"复星医药(02196)控股子公司拟新增开展融资租赁业务","url":"https://stock-news.laohu8.com/highlight/detail?id=2621067566","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621067566?lang=zh_cn&edition=full","pubTime":"2026-03-24 20:53","pubTimestamp":1774356801,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药(02196)发布公告，为进一步拓宽融资渠道，公司部分控股子公司拟与具备相应资质的融资租赁公司/金融租赁公司新增开展融资租赁业务，融资总额不超过人民币6.5亿元，包括：(1)以部分自有资产设备作为转让标的及租赁物开展售后回租、(2)以新购资产设备直租。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1418258.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","BK0196","BK1191","BK1593","BK0060","BK0096","BK0239","BK0012","02196","BK0175","BK1515","BK0028","BK0187","BK0183","600196"],"gpt_icon":0},{"id":"2621757062","title":"复星医药：关于2026年续聘会计师事务所的公告","url":"https://stock-news.laohu8.com/highlight/detail?id=2621757062","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621757062?lang=zh_cn&edition=full","pubTime":"2026-03-24 20:25","pubTimestamp":1774355100,"startTime":"0","endTime":"0","summary":"证券日报网讯3月24日，复星医药发布公告称，2026年3月24日，公司第十届董事会第二十五次会议审议通过了关于本公司2026年续聘会计师事务所及2025年会计师事务所报酬的议案，拟续聘安永华明会计师事务所（特殊普通合伙）为本公司2026年度境内财务报告和内部控制审计机构。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603243682800769.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0183","BK0060","BK0175","BK1593","BK1191","BK0196","600196","BK0028","02196","BK0187","BK0096","BK0012","BK0239","BK0188","BK1515"],"gpt_icon":0},{"id":"2621069488","title":"复星医药(02196)发布2025年报：创新药和全球化双引擎驱动高质量发展","url":"https://stock-news.laohu8.com/highlight/detail?id=2621069488","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621069488?lang=zh_cn&edition=full","pubTime":"2026-03-24 19:16","pubTimestamp":1774350963,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，复星医药(600196.SH，02196)公布2025年度经营业绩。复星医药以创新研发突破与全球化体系升级为双引擎，实现营业收入人民币416.62亿元，同比增长1.45%，其中，创新药品收入98.93亿元，同比增长29.59%;境外收入129.77亿元，同比增长14.87%，两大核心指标实现双增长，深化复星医药高质量发展的底层逻辑。归母净利润33.71亿元，同比增长21.69%;归母扣非净利润23.40亿元，同比增长1.12%;经营活动产生的现金流量净额为52.13亿元，同比增长16.45%，高质量发展底座进一步夯实。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1418167.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0196","BK0187","BK1515","BK0060","BK0183","BK0028","BK1191","159992","BK0012","BK0175","BK0239","BK0096","06978","600196","02196","BK1161","BK1593","BK0188","BK1574"],"gpt_icon":0},{"id":"2621066835","title":"复星医药最新公告：2025年净利润33.71亿元同比增长21.69%","url":"https://stock-news.laohu8.com/highlight/detail?id=2621066835","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621066835?lang=zh_cn&edition=full","pubTime":"2026-03-24 18:40","pubTimestamp":1774348850,"startTime":"0","endTime":"0","summary":"复星医药(600196.SH)发布年报，公司2025年实现营业收入416.62亿元，同比增长1.45%；归属于上市公司股东的净利润为33.71亿元，同比增长21.69%。拟10股派发现金红利3.90元(税前)。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032400033313.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600196","02196"],"gpt_icon":0},{"id":"2621095723","title":"【券商聚焦】交银国际：CXO行情持续回暖 料板块估值倍数合理","url":"https://stock-news.laohu8.com/highlight/detail?id=2621095723","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621095723?lang=zh_cn&edition=full","pubTime":"2026-03-23 10:25","pubTimestamp":1774232735,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际表示，多重利好因素共振下，2025年以来CXO行情持续回暖。该机构建议重点关注标的细分赛道成长力、核心能力布局、盈利和订单增长能见度、地缘风险敞口及估值上升空间。基于此，该机构首推药明合联，首次覆盖并重点推荐凯莱英和康龙化成。","market":"other","thumbnail":"https://static.szfiu.com/news/20250106/ZDQ3YWRiNzU2MjI5OWUwYTllMmZlMTAyNzEyNzQzMTU2MQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/ZDQ3YWRiNzU2MjI5OWUwYTllMmZlMTAyNzEyNzQzMTU2MQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1977006","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BPRC5H50.USD","LU2476274720.SGD","02268","BK1583","09688","BK1617","BK1585","LU0634319403.HKD","LU0417516738.SGD","02196","BK1500","LU0307460666.USD","LU0348767384.USD","LU2488822045.USD","LU2399975544.HKD","BK1593","BK1141","02228","BK1207","LU1115378108.SGD","BK1191","LU0417516571.SGD","02367","LU2476274308.USD","03933","LU1770034418.SGD","03329","01789","IE00B543WZ88.USD","BK1574","BK1161","LU2778985437.USD","BK1588","BK1197","LU0348766576.USD","LU1719994722.HKD","06821","09926","LU1794554557.SGD","01099","LU0348784397.USD","LU0348827113.USD","LU0348735423.USD","LU0540923850.HKD","LU0417516902.SGD","LU1303224171.USD","LU2328871848.SGD","CXO","06160","01530"],"gpt_icon":0},{"id":"2620273402","title":"复星医药（600196）披露控股子公司药品获临床试验批准的公告，3月20日股价下跌1.58%","url":"https://stock-news.laohu8.com/highlight/detail?id=2620273402","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620273402?lang=zh_cn&edition=full","pubTime":"2026-03-20 22:15","pubTimestamp":1774016125,"startTime":"0","endTime":"0","summary":"截至2026年3月20日收盘，复星医药报收于24.86元，较前一交易日下跌1.58%，最新总市值为663.87亿元。该股当日开盘25.29元，最高25.54元，最低24.84元，成交额达3.13亿元，换手率为0.59%。近日，上海复星医药（集团）股份有限公司控股子公司复宏汉霖收到国家药品监督管理局批准，同意其自主研发的纳武利尤单抗生物类似药HLX18用于多种实体瘤治疗开展Ⅰ期临床试验。2025年12月，该药已获美国FDA批准开展Ⅰ期临床试验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032000043260.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","BK0175","BK0187","BK0096","BK1515","BK0183","BK0060","BK1593","BK0239","02196","BK0188","BK0196","600196","BK0028","BK1191"],"gpt_icon":0},{"id":"2620789751","title":"复星医药(600196.SH)： HLX18用于多种实体瘤治疗开展Ⅰ期临床试验获批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2620789751","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620789751?lang=zh_cn&edition=full","pubTime":"2026-03-20 17:00","pubTimestamp":1773997246,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药(600196.SH)公告， 公司控股子公司上海复宏汉霖生物技术股份有限公司及其控股子公司（合称“复宏汉霖”）收到国家药品监督管理局关于同意 HLX18（即重组抗 PD-1 人源化单克隆抗体注射液）用于多种实体瘤治疗开展Ⅰ期临床试验的批准。复宏汉霖拟于条件具备后于中国境内 1开展该药品的相关临床研究。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1416583.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["600196","02196","BK0183","BK0188","BK0060","BK0187","BK1515","BK1593","BK0196","BK0175","BK1191","BK0028","BK0012","BK0096","BK0239"],"gpt_icon":0},{"id":"2620789489","title":"复星医药(600196.SH)：硫代硫酸钠注射液药品注册申请获批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2620789489","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620789489?lang=zh_cn&edition=full","pubTime":"2026-03-20 16:57","pubTimestamp":1773997060,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药(600196.SH)公告，公司控股子公司重庆凯林制药有限公司就硫代硫酸钠注射液的药品注册申请获国家药品监督管理局批准。本次获批适应症为用于氰化物中毒，也可用于砷、汞、铅、铋、碘等中毒。更多港股重磅资讯，下载智通财经app更多港股及海外理财资讯，请点击www.zhitongcaijing.com（搜索“智通财经”）；欲加入智通港股投资群，请加智通客服微信(ztcjkf)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1416581.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK0239","BK0183","BK0175","BK0060","BK0096","BK0028","BK0188","02196","BK0187","BK1191","BK1515","BK0012","BK0196","BK1593","600196"],"gpt_icon":0},{"id":"2619464348","title":"复星医药（600196）披露控股子公司药品获临床试验批准的公告，3月16日股价上涨0.23%","url":"https://stock-news.laohu8.com/highlight/detail?id=2619464348","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619464348?lang=zh_cn&edition=full","pubTime":"2026-03-16 22:40","pubTimestamp":1773672030,"startTime":"0","endTime":"0","summary":"截至2026年3月16日收盘，复星医药报收于25.61元，较前一交易日上涨0.23%，最新总市值为683.9亿元。近日，上海复星医药（集团）股份有限公司控股子公司复宏汉霖收到国家药监局批准，同意HLX07联合斯鲁利单抗注射液和化疗用于晚期鳞状非小细胞肺癌治疗开展临床试验。复宏汉霖拟于条件具备后在中国境内开展相关临床研究。截至2026年3月16日，全球范围内尚无同类联合用药治疗方案获批上市。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031600037042.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK1191","BK0239","BK0096","BK1593","BK0012","600196","BK0196","BK0175","BK0183","BK1515","BK0060","BK0188","02196","BK0187"],"gpt_icon":0},{"id":"2619645427","title":"复星医药(600196.SH)：HLX07联合斯鲁利单抗注射液和化疗用于晚期鳞状非小细胞肺癌(sqNSCLC)治疗获批开展临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2619645427","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619645427?lang=zh_cn&edition=full","pubTime":"2026-03-16 18:44","pubTimestamp":1773657849,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药 发布公告，近日，公司控股子公司上海复宏汉霖生物技术股份有限公司及其控股子公司收到国家药品监督管理局关于同意HLX07联合斯鲁利单抗注射液和化疗用于晚期鳞状非小细胞肺癌治疗开展临床试验的批准。复宏汉霖拟于条件具备后在中国境内开展该治疗方案的相关临床研究。截至本公告日期，于全球范围尚无同类联合用药治疗方案获批上市。截至2025年2月，集团现阶段针对该治疗方案的累计研发投入约为人民币0.93亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1414398.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0187","BK0012","BK1593","BK0196","BK1515","BK0096","BK0175","BK1191","BK0028","BK0188","BK0239","02196","BK0183","BK0060","600196"],"gpt_icon":0},{"id":"2619045967","title":"复星医药最新公告：控股子公司用于治疗雄激素脱发的药品LBP-ShC4获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2619045967","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619045967?lang=zh_cn&edition=full","pubTime":"2026-03-16 17:50","pubTimestamp":1773654632,"startTime":"0","endTime":"0","summary":"复星医药(600196.SH)公告称，控股子公司上海菌济健康科技有限公司收到国家药品监督管理局关于同意LBP-ShC4开展临床试验的批准。LBP-ShC4是复星医药自主研发的活体生物治疗产品，拟用于治疗雄激素脱发（AGA）。截至2026年2月，针对LBP-ShC4的累计研发投入约为0.20亿元。截至本公告日期，于全球范围尚无用于治疗雄激素脱发（AGA）的活体生物治疗产品（包括单药或联合治疗方案）获批上市。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031600025145.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","600196","BK0187","BK1515","BK0012","BK0175","02196","BK1593","BK0060","BK0188","BK0096","BK0239","BK0183","BK0028","BK1191"],"gpt_icon":0},{"id":"2619127710","title":"每周股票复盘：复星医药（600196）三款新药获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2619127710","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619127710?lang=zh_cn&edition=full","pubTime":"2026-03-15 01:40","pubTimestamp":1773510018,"startTime":"0","endTime":"0","summary":"截至2026年3月13日收盘，复星医药报收于25.55元，较上周的25.91元下跌1.39%。本周，复星医药3月10日盘中最高价报26.23元。本周关注点公司公告汇总：复星医药三款自研新药获临床试验批准。复星医药控股子公司上海复星医药产业发展有限公司收到国家药品监督管理局批准，同意其自主研发的口服小分子创新药FXS0683片用于血液系统恶性肿瘤开展临床试验。复星医药产业拟于条件具备后在中国境内开展I期临床研究。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031500000277.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0188","BK0187","BK0028","BK0196","BK1593","BK0096","600196","BK1515","BK0175","BK0012","BK0183","BK0060","BK1191","02196"],"gpt_icon":0},{"id":"2619719840","title":"复星医药(600196.SH)控股子公司FXS0683片获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2619719840","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619719840?lang=zh_cn&edition=full","pubTime":"2026-03-13 17:30","pubTimestamp":1773394256,"startTime":"0","endTime":"0","summary":"复星医药(600196.SH)发布公告，近日，公司控股子公司上海复星医药产业发展有限公司(简称“复星医药产业”)收到国家药品监督管理局关于同意FXS0683片(简称“FXS0683”)用于血液系统恶性肿瘤开展临床试验的批准。复星医药产业拟于条件具备后于中国境内开展FXS0683的I期临床研究。","market":"sg","thumbnail":"https://img.zhitongcaijing.com/astock/13.jpg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/astock/13.jpg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1413656.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK0012","BK0175","BK0187","BK0096","BK1515","BK0183","BK0060","BK1593","BK0239","02196","BK0188","BK0196","600196","BK0028","BK1191"],"gpt_icon":0},{"id":"2618184647","title":"每日卖空追踪 | 复星医药 03月12日卖空量成交3.65万股，卖空比例为2.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618184647","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618184647?lang=zh_cn&edition=full","pubTime":"2026-03-12 16:30","pubTimestamp":1773304229,"startTime":"0","endTime":"0","summary":"复星医药北京时间03月12日，跌0.87%，卖空量成交3.65万股，较上一交易日减少43.85%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260312163352a6ba5121&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260312163352a6ba5121&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","BK1593","BK1515","02196"],"gpt_icon":0},{"id":"2618416971","title":"复星医药03月11日主力净流出4.0万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2618416971","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618416971?lang=zh_cn&edition=full","pubTime":"2026-03-11 16:15","pubTimestamp":1773216955,"startTime":"0","endTime":"0","summary":"03月11日, 复星医药股价跌1.46%，报收19.57元，成交金额2605.0万元，换手率0.24%，振幅2.37%，量比0.42。复星医药今日主力资金净流出4.0万元，上一交易日主力净流入106.3万元。该股近5个交易日上涨5.85%，主力资金累计净流入564.1万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流出77.1万元，其中净流出天数为11日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311162035a6b789d5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311162035a6b789d5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","BK1593","BK1515","02196"],"gpt_icon":0},{"id":"2618401971","title":"复星国际“瘦身健体”：没了快乐富足 但保住了健康","url":"https://stock-news.laohu8.com/highlight/detail?id=2618401971","media":"投资AB面","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618401971?lang=zh_cn&edition=full","pubTime":"2026-03-11 16:02","pubTimestamp":1773216172,"startTime":"0","endTime":"0","summary":"作为国内知名民营企业，复星国际眼前就正遭受着“瘦身健体”之苦。由于业务体系过于繁杂，复星国际后来将公司业务笼统地归结为健康、快乐、富足、智造四大业务板块。叠加当时房地产企业纷纷暴雷，复星国际由此走上了“健体瘦身”之路。“快乐”和“富足”已然成为公司亏损最为严重的两大业务板块。好在公司还有复星医药一张“王牌”，才保住了健康业务不止于亏损。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026031119142697ad9c25&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026031119142697ad9c25&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02196","00656","BK1191","BK1230","BK1593","BK1515"],"gpt_icon":0},{"id":"2618971477","title":"前复星医药高管创业，刚刚拿下近亿元天使轮融资","url":"https://stock-news.laohu8.com/highlight/detail?id=2618971477","media":"丁香园 Insight 数据库","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618971477?lang=zh_cn&edition=full","pubTime":"2026-03-11 15:26","pubTimestamp":1773213967,"startTime":"0","endTime":"0","summary":"3 月 11 日，璞诺智药宣布顺利完成近亿元天使轮融资。本轮融资由深耕医疗健康领域的专业创投机构华盖资本和博远资本共同领投，薄荷天使基金等专业投资机构跟投。全面推进降解剂核心管线 PPI-101的 IND 申报 ，作为全新机制的 RBM39 分子胶降解剂，PPI-101 聚焦高临床未满足需求的瘤种，具备显著的肿瘤组织渗透和杀伤能力。璞诺智药成立于 2024 年，总部位于苏州，是一家聚焦“难成药靶点”的创新药企。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026031116181195484ca3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026031116181195484ca3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1593","BK1515","BK1191","02196"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.fosunpharma.com","stockEarnings":[{"period":"1week","weight":-0.0227},{"period":"1month","weight":-0.0868},{"period":"3month","weight":-0.077},{"period":"6month","weight":-0.2301},{"period":"1year","weight":0.2856},{"period":"ytd","weight":-0.0312}],"compareEarnings":[{"period":"1week","weight":-0.0265},{"period":"1month","weight":-0.0645},{"period":"3month","weight":-0.0187},{"period":"6month","weight":-0.0303},{"period":"1year","weight":0.0853},{"period":"ytd","weight":-0.0115}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"上海复星医药（集团）股份有限公司是一家主要从事医药产品研发、制造与销售的中国公司。该公司经营五个分部。制药分部主要从事创新药、成熟医药产品制造和疫苗业务。医疗器械与医学诊断分部主要从事分子诊断、免疫诊断、微生物诊断等医疗美容器械的制造和销售。医疗健康服务分部主要从事线上线下一体化医疗服务平台的经营。医药分销和零售分部主要从事医药产品的批发零售。其他分部从事其他医药相关业务。该公司的产品主要用于肿瘤、免疫、中枢神经等治疗领域。","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":-0.044492},{"month":2,"riseRate":0.714286,"avgChangeRate":0.036178},{"month":3,"riseRate":0.571429,"avgChangeRate":0.041118},{"month":4,"riseRate":0.384615,"avgChangeRate":0.03076},{"month":5,"riseRate":0.461538,"avgChangeRate":0.035265},{"month":6,"riseRate":0.461538,"avgChangeRate":-0.026545},{"month":7,"riseRate":0.615385,"avgChangeRate":0.027595},{"month":8,"riseRate":0.307692,"avgChangeRate":-0.041651},{"month":9,"riseRate":0.461538,"avgChangeRate":0.011609},{"month":10,"riseRate":0.461538,"avgChangeRate":0.020359},{"month":11,"riseRate":0.428571,"avgChangeRate":0.034495},{"month":12,"riseRate":0.428571,"avgChangeRate":0.015123}],"exchange":"SEHK","name":"复星医药","nameEN":"FOSUN PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"复星医药(02196)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供复星医药(02196)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"复星医药,02196,复星医药股票,复星医药股票老虎,复星医药股票老虎国际,复星医药行情,复星医药股票行情,复星医药股价,复星医药股市,复星医药股票价格,复星医药股票交易,复星医药股票购买,复星医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"复星医药(02196)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供复星医药(02196)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}